Core Viewpoint - Heng Rui Medicine has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, which is the first EZH2 inhibitor independently developed in China, aimed at adult patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one line of systemic therapy [1] Group 1: Product Development - SHR2554 tablets are a new, highly efficient, and selective oral EZH2 inhibitor developed by the company [1] - The drug is positioned to address a significant unmet medical need in the treatment of R/RPTCL [1] Group 2: Market Context - The approval of SHR2554 follows the earlier approvals of similar drugs, such as Tazverik by Epizyme in the US and Ezharmia by Daiichi Sankyo in Japan, indicating a growing market for EZH2 inhibitors [1] - Tazverik is projected to have global sales of approximately $51 million in 2024, highlighting the commercial potential for EZH2 inhibitors [1] Group 3: Investment and R&D - The cumulative R&D investment for the SHR2554 project has reached approximately 213 million yuan [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 孫飄揚先生 中國上海 2025年9月1日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-134 ...

主力资金净流出的行业有23个，非银金融行业主力资金净流出规模居首，全天净流出资金80.79亿元， 其次是计算机行业，净流出资金为70.10亿元，净流出资金较多的还有电力设备、汽车、国防军工等行 业。 医药生物行业今日上涨2.79%，全天主力资金净流入34.75亿元，该行业所属的个股共474只，今日上涨 的有373只，涨停的有14只；下跌的有98只，跌停的有1只。以资金流向数据进行统计，该行业资金净流 入的个股有216只，其中，净流入资金超亿元的有16只，净流入资金居首的是药明康德，今日净流入资 金10.40亿元，紧随其后的是长春高新、恒瑞医药，净流入资金分别为5.99亿元、5.24亿元。医药生物行 业资金净流出个股中，资金净流出超亿元的有7只，净流出资金居前的有博瑞医药、爱尔眼科、美年健 康，净流出资金分别为2.11亿元、1.86亿元、1.82亿元。（数据宝） 医药生物行业资金流入榜 沪指9月1日上涨0.46%，申万所属行业中，今日上涨的有24个，涨幅居前的行业为通信、综合，涨幅分 别为5.22%、4.27%。医药生物行业今日上涨2.79%。跌幅居前的行业为非银金融、银行，跌幅分别为 1.28%、1.03%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年9月1日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-133 ...

Core Viewpoint - Heng Rui Medicine (600276.SH) announced that its subsidiary, Fujian Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration (NMPA) for the drug listing application of HRS9531 injection [1] Group 1 - The drug HRS9531 is intended for long-term weight management in adults with a body mass index (BMI) of ≥28 kg/m² (obesity) or ≥24 kg/m² (overweight) with at least one weight-related comorbidity, such as high blood sugar, hypertension, dyslipidemia, obstructive sleep apnea, or fatty liver [1]

恒瑞医药（600276）(600276.SH)发布公告，近日，公司收到国家药品监督管理局(简称"国家药监局")的 通知，附条件批准公司自主研发的1类创新药泽美妥司他片(SHR2554片)上市，用于既往接受过至少1线 系统性治疗的复发或难治外周T细胞淋巴瘤(R/RPTCL)成人患者。泽美妥司他片是中国首个自主研发的 EZH2抑制剂。 ...

Group 1 - The core viewpoint of the report indicates that the China Europe Medical Health Fund, managed by Guo Lan and Zhao Lei, has achieved a year-to-date return of 28.82%, outperforming other funds in the same category [1] - The fund has increased its holdings in the innovative pharmaceutical and medical device industry chain, particularly in Elysium (688578.SH) [1] - The top ten holdings of the fund include prominent companies such as WuXi AppTec (603259), Hengrui Medicine (600276), and Kanglong Chemical (300759), with significant investments in these firms [2][3] Group 2 - Elysium's shareholding has increased by 2627.32% compared to the end of last year, indicating a strong bullish sentiment [3] - Notable reductions in holdings include Hengrui Medicine, which decreased from 67.17 million shares to 57.49 million shares, and Kanglong Chemical, which fell from 72.29 million shares to 63.40 million shares [3] - The report highlights that major players like Mindray Medical and Aier Eye Hospital have dropped to the list of hidden heavyweights due to significant reductions in their holdings [3] Group 3 - The report outlines the cumulative sell amounts for various stocks, with Mindray Medical leading at approximately 1.77 billion yuan, followed by Hengrui Medicine at around 749 million yuan [4] - The report emphasizes that the pharmaceutical industry will continue to rely on innovation, consumer recovery, and domestic substitution as core growth drivers in the second half of the year [4] - The company plans to maintain a long-term value investment framework, focusing on innovative pharmaceuticals, OTC, and consumer healthcare sectors [5]

Group 1 - The Hong Kong pharmaceutical sector experienced a significant rise, with the Hang Seng Biotechnology Index closing up over 5%, driven by favorable policies and strong performance in earnings [1] - The National Healthcare Security Administration announced the adjustment list for the 2025 medical insurance and commercial insurance innovative drug directory, which includes several heavyweight innovative drugs, enhancing market access expectations [1] - Several pharmaceutical companies reported robust performance in the first half of the year, such as BeiGene with a 46% year-on-year revenue growth and achieving half-year profitability for the first time, and Heng Rui Medicine reaching record highs in revenue and profit, improving the sector's attractiveness [1] Group 2 - The international collaboration and overseas expansion of innovative drugs have become significant catalysts, with Chinese pharmaceutical companies completing 83 license-out transactions totaling over $84.5 billion, setting a historical record [1] - The partnership between 3SBio and Pfizer, valued at $6.05 billion for dual antibody licensing, highlights global market recognition of domestic innovative drugs [1] - Hong Kong has recently introduced simplified registration policies that recognize mainland review data, facilitating internationalization for innovative drug companies and further expanding industry growth potential [3] Group 3 - The upcoming global academic conferences, such as the World Lung Cancer Conference in September and the European Society for Medical Oncology Annual Meeting in October, will see multiple companies showcasing core clinical data, which may serve as short-term stock price catalysts [3] - Institutions believe that the long-term logic of the innovative drug sector remains unchanged, and the expectation of interest rate cuts by the Federal Reserve is strengthening liquidity, leading to continued capital allocation towards leading Hong Kong pharmaceutical stocks [4]

Core Viewpoint - The weight loss drug sector has shown a significant increase, with a rise of 2.99% as of September 1, ranking it seventh among concept sectors, driven by strong performances from several stocks [1][2]. Group 1: Sector Performance - The weight loss drug sector saw 48 stocks increase in value, with notable gainers including Baihua Pharmaceutical (up 10.91%), Dezhan Health (up 10.00%), and Health元 (up 9.98%) [1][2]. - Conversely, stocks such as Sichuan Shuangma, Nawei Technology, and Deyuan Pharmaceutical experienced declines, with drops of 3.73%, 3.61%, and 1.64% respectively [1][2]. Group 2: Capital Flow - The weight loss drug sector attracted a net inflow of 1.528 billion yuan, with 35 stocks receiving net inflows, and 6 stocks exceeding 100 million yuan in net inflows [2][3]. - Leading the net inflow was Heng Rui Pharmaceutical, which saw a net inflow of 524 million yuan, followed by Fosun Pharmaceutical (233 million yuan), Health元 (213 million yuan), and Yi Pin Hong (128 million yuan) [2][3]. Group 3: Stock Specifics - Health元, Dezhan Health, and Baihua Pharmaceutical had the highest net inflow ratios at 28.67%, 26.23%, and 16.34% respectively [3]. - Specific stock performances included Heng Rui Pharmaceutical (up 3.20% with a turnover rate of 1.37%), Fosun Pharmaceutical (up 6.38% with a turnover rate of 4.71%), and Health元 (up 9.98% with a turnover rate of 3.05%) [3][4].

Core Viewpoint - Heng Rui Medicine (600276.SH) has received conditional approval from the National Medical Products Administration for its self-developed innovative drug, SHR2554 tablets, which is the first EZH2 inhibitor developed in China, aimed at adult patients with relapsed or refractory peripheral T-cell lymphoma who have previously undergone at least one line of systemic therapy [1] Company Summary - The company has developed SHR2554 tablets, marking a significant milestone as it is the first EZH2 inhibitor independently developed in China [1] - The approval is specifically for adult patients with relapsed or refractory peripheral T-cell lymphoma, indicating a targeted therapeutic application [1] Industry Summary - The approval of SHR2554 tablets highlights advancements in the oncology sector, particularly in the development of innovative treatments for complex hematological malignancies [1] - The introduction of the first EZH2 inhibitor in the Chinese market may enhance competition and innovation within the pharmaceutical industry, particularly in the field of cancer treatment [1]